ME Therapeutics Holding (XCNQ:METX) Debt-to-EBITDA : 0.00 (As of Feb. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ME Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$0.00 Mil. ME Therapeutics Holding's annualized EBITDA for the quarter that ended in Feb. 2024 was C$-0.57 Mil. ME Therapeutics Holding's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ME Therapeutics Holding's Debt-to-EBITDA or its related term are showing as below:

XCNQ:METX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.43 Med: -0.72 Max: -0.01
Current: -0.01

During the past 2 years, the highest Debt-to-EBITDA Ratio of ME Therapeutics Holding was -0.01. The lowest was -1.43. And the median was -0.72.

XCNQ:METX's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs XCNQ:METX: -0.01

ME Therapeutics Holding Debt-to-EBITDA Historical Data

The historical data trend for ME Therapeutics Holding's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Debt-to-EBITDA Chart

ME Therapeutics Holding Annual Data

Trend

Aug22

Aug23

Debt-to-EBITDA

-1.43

-0.01

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.25	-	-	-0.03	-

Competitive Comparison of ME Therapeutics Holding's Debt-to-EBITDA

For the Biotechnology subindustry, ME Therapeutics Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Debt-to-EBITDA falls into.

ME Therapeutics Holding Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ME Therapeutics Holding's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.04	+	0)	/	-6.513
	=	-0.01

ME Therapeutics Holding's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.572
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.

ME Therapeutics Holding (XCNQ:METX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

ME Therapeutics Holding Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

Q9T:Germany

Address

177 Robson Street, Vancouver, BC, CAN, V6B 0N3

Website

https://www.metherapeutics.com

ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines